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Purpose: This study aimed to explore whether cardiopulmonary fitness, echocardiographic 8 
measures and relative exercise intensity were associated with high sensitivity cardiac troponin T 9 
(hs-TNT) rise and normalization following a marathon. 10 
Methods: Nighty-eight participants (83 males and 15 females; 38.72 ± 3.63 years) were subjected 11 
to echocardiographic assessment and a cardiopulmonary exercise test (CPET) before the race. Hs-12 
TNT was measured before, immediately after and at 24, 48, 96, 144 and 192 h post-race. Heart 13 
rate (HR) was recorded throughout the marathon. 14 
Results: Hs-TNT significantly increased from pre to post-race (5.74 ± 5.29 vs 50.4 ± 57.04 ng/L; 15 
p<0.01) and 95% of the participants displayed values exceeding the Upper Reference Limit 16 
(URL). 24 h post-race, 39% of the runners still displayed concentrations above URL (High hs-17 
TNT group); and until 96 h post-race Hs-TNT values remained significantly different from 18 
baseline. Hs-TNT rise was correlated with relative exercise intensity: marathon speed %VVT2 19 
(r=0.22; p<0.05); mean HR (r=0.41; p<0.01); mean HR%VT2 (r=0.30; p<0.01); and mean HR%MAX 20 
(r=0.32; p<0.01). Moreover, High hs-TNT group performed the marathon at a higher relative 21 
speed: Speed %VVT2 (88.21 ± 6.53 vs 83.49 ± 6.54%; p<0.01) and Speed %VVMAX (72 ± 4.25 vs 22 
69.40 ± 5.53%; p<0.01). 23 
Conclusion: Post-race Hs-TNT was above URL in barely all of the runners. Magnitude of Hs-24 
TNT rise was correlated with exercise mean HR whereas their normalization kept relationship 25 
with marathon speed relative to second ventilatory threshold and CPET peak velocity. 26 
Cardiopulmonary fitness, echocardiographic measures and training history were unrelated to Hs-27 
TNT rise and normalization. 28 
 29 
 30 






































































hs-TNT High-sensitive cardiac troponin T 34 
CPET  Cardiopulmonary exercise test 35 
HR  Heart rate 36 
URL  Upper reference limit 37 
BMI  Body mass index 38 
VO2max Maximum oxygen uptake 39 
RER  Respiratory exchange ratio 40 
VT2  Second ventilatory threshold 41 
RVEDD Right ventricular end diastolic diameter 42 
LVEDD Left ventricular end diastolic diameter 43 
LVESD Left ventricular end systolic diameter 44 
IVS  Interventricular septum at the end of diastole 45 
PW  Posterior wall at the end of diastole 46 
LVEF  Left ventricular ejection fraction 47 
ECLIA  Electrochemiluminescence technology 48 
LoB  Limit of the blank 49 




































































1. Introduction  51 
 52 
The number of recreational/non-elite athletes participating in marathons is yearly increasing and 53 
it is becoming well established that such an strenuous physical effort provokes an acute release 54 
of cardiac damage biomarkers (i.e., troponin), making them rise above clinically significant 55 
values (levels greater than the 99th percentile of a healthy reference population, Upper Reference 56 
Limit, URL) (Gresslien and Agewall 2016; Regwan et al. 2010; Shave et al. 2007). Although a 57 
debate exists about the pathological vs. physiological meaning of such cardiac response to 58 
exercise, available evidence majorly supports the latter reasoning (Baker et al. 2019; Gresslien 59 
and Agewall 2016; Kleiven et al. 2019; Vroemen et al. 2019). In fact, specific algorithms have 60 
been proposed for the management of athletes attending emergency departments with clinical 61 
symptoms compatible with a cardiac event after exercise (Baker et al. 2019).  62 
 63 
However, whether the magnitude of post-exercise elevation in troponin concentration is related 64 
or not with relative intensity at which a marathon is performed is still a relevant and open-to-65 
debate question (Brzezinski et al. 2019; Donaldson et al. 2019). Indeed, several studies have 66 
attempted to identify predictors of exercise-induced troponin release (Eijsvogels et al. 2015; 67 
Fortescue et al. 2007; Kleiven et al. 2019; Kosowski et al. 2019; Mehta et al. 2012; Neilan et al. 68 
2006; Paana et al. 2019; Richardson et al. 2018), but as far as we are aware only one investigation 69 
included objectively-measured marathon relative intensity (i.e., speed and HR as percentages of 70 
maximums attained at a cardiopulmonary exercise test) (Richardson et al. 2018). On the other 71 
hand, no previous investigation have checked whether normalization of high sensitivity cardiac 72 
troponin (hs-TNT) levels is associated with either baseline echocardiographic and fitness 73 
variables or relative intensity at which the race has been performed. Measurement using high 74 
sensitivity analysis now allows improved accuracy, reliability and identification of those above 75 
reference limits compared to second and third-generation assays (Giannitsis et al. 2010; Vilela et 76 
al. 2014). Peak hs-TnT release is usually observed within 3 to 6h following a marathon (Baker et 77 




































































notwithstanding, a percentage of athletes still display values exceeding the URL at this time point 79 
(between 22% and 27%) (Baker et al. 2019; Scherr et al. 2011). 80 
 81 
Therefore, the aim of this study was twofold. Firstly, we were interested in assessing whether the 82 
degree of post-exercise hs-TNT rise was associated with any of the following variables: baseline 83 
echocardiographic, cardiovascular fitness and training variables; or relative intensity at which a 84 
marathon is performed. Secondly, we wanted to explore if any of the abovementioned variables 85 
was different among those runners who normalize hs-TNT within the initial 24 h post-exercise 86 
and those who do not. Our study hypothesis was that relative exercise intensity derived from a 87 
cardiopulmonary exercise test would be related to both immediate and 24h post-race hs-TNT 88 
concentration. We also hypothesized that baseline echocardiographic and cardiovascular fitness 89 




































































2. Methods 91 
 92 
2.1. Participants 93 
All participants of the Valencia Fundacion Trinidad Alfonso EDP 2016 Marathon received an 94 
invitation email to participate in the study. Two information seminars were organized in order to 95 
fully explain the study design (aims, measurements, etc.) to those individuals who accepted the 96 
invitation (N = 456). A total of 98 runners (83 males and 15 females) were selected to participate 97 
in this study, according to the following inclusion criteria: age between 30 and 45 years; body 98 
mass index (BMI) between 16 and 24.99 kg.m-2; previous marathon experience; having a 99 
performance best time in marathon between 3 and 4 hours for males and 3:30 and 4:30 hours for 100 
females; and individuals who were free from cardiac or renal disease and from taking any 101 
medication on a regular basis. Participant characteristics are presented in Table 1. All individuals 102 
included in the current study were fully informed and gave their written consent to participate. 103 
The research was conducted according to the Declaration of Helsinki and it was approved by the 104 
Research Ethics Committee of the Jaume I University of Castellon. This study is enrolled in the 105 
ClinicalTrails.gov database, with the code number NCT03155633 (www.clinicaltrials.gov). 106 
 107 
** Insert Table 1 near here ** 108 
 109 
2.2. Cardiopulmonary exercise test 110 
Cardiopulmonary exercise tests (CPET) were performed on a treadmill (H/P/cosmos pulsar, 111 
H/P/cosmos sports & medical GmbH, Nussdorf-Traunstein, Germany) between 2 to 4 weeks prior 112 
to the marathon. Pulmonary VO2 and VCO2 were measured breath-by-breath using an automated 113 
online system (Oxycon Pro system, Jaeger, Würzburg, Germany). Gas analysis system was 114 
calibrated for ambient temperature and humidity, air flow and VO2 and VCO2 concentrations 115 
(with a 4.96% CO2 – 12.10% O2 gas mixture) before each testing session according to 116 
manufacturer instructions (Rietjens et al. 2001). CPET protocol consisted of 3 min warm up at 6 117 




































































exhaustion. A 3-min constant speed stage at 11 km.h-1  for women and 12 km.h-1 for men was 119 
included in the protocol so as to enable running economy measurements. Maximum oxýgen 120 
uptake (VO2max) values were accepted when a plateau (an increase of <2ml/kg/min) or a decline 121 
in VO2 was reached despite increasing workloads and a respiratory exchange ratio (RER) above 122 
1.15 was achieved. If this criteria was not met, a VO2peak value was taken, defined as the highest 123 
VO2 measured over a 30 seconds period. Second ventilatory threshold (VT2)  was estimated from 124 
gas exchange data by two independent researchers following a validated standard methodology 125 
as previously described (Lucia et al. 2000).  126 
 127 
2.3. Echocardiography 128 
Transthoracic echocardiography was performed at baseline with a Philips HD5 Diagnostic 129 
Ultrasound System (Philips Ultrasound, Bothell, Washington USA 98021). All two-dimensional 130 
images were acquired from standard parasternal and apical windows by the same experienced 131 
echocardiographist following international recommendations for chambers quantification 132 
(Mitchell et al. 2019). The study included the following two-dimensional measures: Right 133 
Ventricular End Diastolic Diameter (RVEDD), Left Ventricular End Diastolic Diameter 134 
(LVEDD), Left Ventricular End Systolic Diameter (LVESD), Interventricular Septum at the end 135 
of diastole (IVS) and Posterior Wall at the end of diastole (PW). Left Ventricular Ejection 136 
Fraction (LVEF) was assessed according to Teichholz Method. Finally, Left Ventricular Mass 137 
was calculated using Devereux modified method and Penn modified method. 138 
 139 
2.4. Blood sampling and analysis 140 
Blood samples were collected at baseline (the day before the race), after finishing the marathon 141 
and at 24, 48, 96, 144 h and 192 h post-race. Samples were collected from antecubital veins by 142 
venipuncture using BD Vacutainer PST II tubes, centrifuged at 3500 rpm for ten minutes and 143 
transported at 4°C within 2 hours after their extraction to the Vithas 9 de Octubre Hospital 144 
(Valencia), as previously published (Bernat-Adell et al. 2019). Hs-TNT was measured 145 




































































electrochemiluminescence technology (ECLIA), using a Cobas e411 analyzer (Roche 147 
Diagnostics, Penzberg, Germany). Detailed descriptions of this assay have been previously 148 
published (Giannitsis et al. 2010). The Limit of the Blank (LoB) of this assay is 3 ng/L and the 149 
URL, defined as the 99th percentile of a healthy population, 14 ng/L. The approximate hs-TnT 150 
equivalent to the upper limit of 30 ng/L for the 4th generation cardiac troponin T assay is 50 ng/L 151 
(Giannitsis et al. 2010). For the blood sample obtained immediately after the race, values were 152 
corrected due to changes in plasma volume and the hemoconcentration caused by dehydration 153 
using Dill and Costill formula (Dill and Costill 1974). 154 
 155 
2.5. Exercise intensity monitoring 156 
On the morning of the marathon, participants were given a Polar M400 HR monitor (Kempele, 157 
Finland) and a GENEActiv accelerometer (Activinsights, Ltd., Kimbolton, Cambridgeshire, 158 
United Kingdom). Mean and peak HR (highest HR maintained for at least 1 min) during the 159 
marathon (both in absolute values and expressed as percentage of HR at VT2 and maximum HR 160 
reached at the CPET) were retained for statistical analyses. Time above HR at VT2 and time at 161 
extremely vigorous intensity derived from accelerometer data were also considered (Hernando et 162 
al. 2018). Finally, marathon finish time was obtained using the ChampionChip time registration 163 
(ChampionChip®, MYLAPS, The Netherlands), out of which mean running speed was calculated 164 
(both in absolute values and expressed as a percentage of the velocity at VT2 and the peak velocity 165 
reached at the CPET) and  retained for statistical analyses. 166 
 167 
2.6. Statistical analysis 168 
Statistical analyses were carried out using the Statistical Package for the Social Sciences software 169 
(IBM SPSS Statistics for Windows, version 22.0, IBM Corp., Armonk, NY). Normal distribution 170 
of the variables was a priori verified through the Kolmogorov Smirnov test, obtaining values of 171 
p<0.05 for all Troponin related variables. This result motivated the usage of nonparametric tests. 172 
Friedman and Wilcoxon tests were used to assess differences in Hs-TNT between pre-race and 173 




































































were employed to analyze possible relationships between baseline echocardiographic and 175 
cardiopulmonary test variables (i.e., VO2max, maximal speed and speed attained at VT2), 176 
training-related variables, exercise intensity and post-race change in Hs-TNT. To that purpose, 177 
post-race Hs-TNT values for each subject were related to the individual baseline level (values 178 
below the LoB were set to 3 ng/l) to calculate delta scores (∆): ∆ (fold increase) = (post-race value 179 
– pre-race value)/pre-race value.  180 
 181 
Additionally, 24h post-race hs-TNT data set was splitted into two groups based on the URL for 182 
this biomarker (High hs-TNT and Low hs-TNT groups) and possible differences in  baseline 183 
echocardiographic and cardiopulmonary test variables, training-related variables and exercise 184 
intensity variables were assessed using a Mann-Whitney U test. The meaningfulness of the 185 
significant outcomes was estimated through Cohen’s d effect size: a d<0.5 was considered small; 186 
between 0.5-0.8, moderate; and greater than 0.8, large (Thomas et al. 2005). Likewise, 187 
correlations >0.5 were considered strong, 0.3-0.5, moderate and <0.3, small. The significance 188 




































































3. Results 190 
 191 
From the initial sample of 98 participants, 88 runners finished the marathon and we could obtain 192 
whole data from 77 athletes, 64 men (83%) and 13 women (17%), who constitute the final sample 193 
of the study. Their average finishing time was 3h:35min ± 20min, ranging from 2h:58min to 194 
4h:35min. No signs of ischemia were detected in any athlete in the exercise electrocardiogram 195 
performed during the CPET. 196 
 197 
The concentration of hs-TNT significantly and largely increased from pre-race to post-race (5.74 198 
± 5.29 vs 50.4 ± 57.04 ng/L; p<0.001; d=1.08) (see Figure 1). It significantly dropped from 199 
immediately post-race to 24 h post-race (50.4 ± 57.04 ng/L vs 15.55 ± 14.29; p<0.001; d=0.84), 200 
and from 24 h post-race to 48 h post-race (15.55 ± 14.29 vs 11.49 ± 14.12; p<0.001; d=0.29). 201 
However, hs-TNT remained largely elevated at 24 h (p<0.001; d=0.86) and moderately elevated 202 
at 48 h post-race (p<0.001; d=0.52) compared to pre-race values. At 96 h it significantly dropped 203 
again from 48 h measurement (5.02 ± 4.53 vs 11.49 ± 14.12; p<0.001; d=0.63) and then it 204 
normalized their values in relation to pre-race (p=0.347). At baseline, concentrations of hs-TNT 205 
were negative (i.e., below the LoB) in 15 participants (19%) and only 4 runners (5%) displayed a 206 
value above the URL. After the race, all of the athletes showed measurable values of hs-TNT; 73 207 
of those runners (95%) displayed values exceeding the URL and 25 participants (32%) surpassed 208 
the threshold for suspicion of myocardial injury. The post-race range of concentrations varied 209 
from 9.3 to 431.3 ng/L. At 24 h measurement, 30 runners (39%) still displayed values exceeding 210 
the URL but only in 3 participants (4%) hs-TNT concentration was above the threshold for 211 
suspicion of myocardial injury. The 24 h post-race range of concentrations varied from <3 to 92.8 212 
ng/L. 213 
 214 





































































The results from correlational analyses are presented in Table 2 and 3. No relationship was found 217 
between post-race hs-TNT and self-reported training history. Similarly,  hs-TNT rise was 218 
uncorrelated with cardiopulmonary test variables. Regarding baseline echocardiographic 219 
measures, only LVESD showed a significant but small association with post-race hs-TNT (r=-220 
0.26; p=0.018). However, rise in hs-TNT was significantly and moderately correlated with 221 
marathon mean HR (r=0.41; p<0.001), marathon mean HR%VT2 (r=0.30; p=0.007) and marathon 222 
mean HR%MAX (r=0.32; p=0.004). It also displayed a significant but small association with 223 
marathon speed %VVT2 (r=0.22; p=0.042). On the contrary, no relationships were found between 224 
post-race hs-TNT and marathon peak HR, time spent above HRVT2 and time at extremely vigorous 225 
intensity zone measured by accelerometry. The results from Mann-Whitney U test revealed no 226 
differences between High and Low hs-TNT groups in baseline echocardiographic and 227 
cardiopulmonary exercise test variables and self-reported training history. Conversely, marathon 228 
speed, either relativized by VT2 or maximum attained at the cardiopulmonary exercise test, were 229 
significantly and moderately greater in the High hs-TNT group (p=0.002 and p=0.009 230 
respectively; d=0.73 and d=0.52 respectively). 231 
 232 




































































4. Discussion 234 
 235 
The main purposes of the present study were to identify possible predictors of exercise-induced 236 
troponin release and explore whether runners who do not normalize hs-TNT within the initial 24h 237 
post-exercise display different values in baseline echocardiographic, cardiovascular fitness and 238 
training variables or performed the marathon at a higher relative intensity. As we hypothesized, 239 
mean HR during the marathon (both the absolute value and the percentage of the HR in VT2 and 240 
the peak HR reached at the CPET) was directly correlated with post-race rise in hs-TNT; whereas 241 
athletes who still displayed a hs-TNT concentration above URL 24h following the race performed 242 
the marathon at a significantly higher relative speed (i.e., expressed as a percentage of either the 243 
speed at VT2 or the peak speed reached at the CPET). However, contrary to our expectations, 244 
baseline echocardiographic and cardiovascular fitness variables were not associated with hs-TNT 245 
rise and normalization, except for a small association between LVESD and post-race hs-TnT, 246 
which seems clinically unimportant.  247 
 248 
The percentage of runners with post-race hs-TNT values above URL in our study (95%) falls 249 
within the range previously reported following a road marathon (between 86% and 100%) 250 
(Mingels et al. 2009; Paana et al. 2019; Richardson et al. 2018; Roca et al. 2017; Scherr et al. 251 
2011). Such previous studies unfortunately did not report the percentage of participants who 252 
surpassed the threshold for suspicion of myocardial injury (i.e., 50 ng/L), so we can not compare 253 
our results at that point. Our finding of a direct relationship between post-exercise rise in hs-TNT 254 
and marathon speed %VVT2 suggest that runners who performed the marathon at a higher relative 255 
intensity released greater amounts of cardiac troponins. Previous studies assessing the relationship 256 
between in hs-TNT response and exercise intensity in endurance competitions have been 257 
conflicting: some studies found a direct correlation (Kleiven et al. 2019; Martinez-Navarro et al. 258 
2019), whereas others found an inverse correlation (Eijsvogels et al. 2015; Jassal et al. 2009; Roca 259 
et al. 2017; Scherr et al. 2011) or no correlation (Bishop et al. 2019; Kosowski et al. 2019; Mingels 260 




































































speed (i.e., expressed as a percentage of maximal speed and speed attained at VT2 in a CPET) 262 
was considered. The above suggestion that greater relative intensity is associated with a larger 263 
release of cardiac troponin is reinforced in our study by the relationship between post-race hs-264 
TNT and marathon mean HR. Such association agrees with previous results from Richardson et 265 
al. (2018) but contrasts with other previous studies, who showed no association between post-266 
exercise hs-TNT and mean HR during either a 91-km mountain bike race or a marathon (Kleiven 267 
et al. 2019; Kosowski et al. 2019; Scherr et al. 2011). The fact that in this latter studies participants 268 
reported HR data from different personal sportwatches (Kleiven et al. 2019; Scherr et al. 2011) 269 
and HR was measured in 1-min intervals (Kosowski et al. 2019) could explain this disagreement. 270 
 271 
Additionally, our percentage of runners displaying a hs-TNT value above URL (39%) 24 h post-272 
race is greater than that showed following a road marathon (between 17 and 27%) (Baker et al. 273 
2019; Mingels et al. 2009; Scherr et al. 2011) and a 91-km mountain bike race (18%) (Kleiven et 274 
al. 2019). Moreover, we are unaware of previous investigations showing that athletes who still 275 
displayed a hs-TNT concentration above URL 24h following the marathon performed the race at 276 
a significantly higher relative speed (i.e., expressed as a percentage of either the speed at VT2 or 277 
the peak speed reached at the CPET). In view of these results, athletes who are capable of running 278 
the marathon at a greater relative intensity, which it has been largely demonstrated to be a key 279 
performance factor (di Prampero et al. 1986), are those who sustain greater cardiac strain. 280 
Therefore, it becomes crucial for such higher-performing athletes to precisely balance training 281 
and recovery following strenuous competitions such as a marathon. 282 
 283 
The absence of any relationship between post-race hs-TNT and self-reported training history 284 
coincides with Kleiven et al. (2019) but differs, however, with other previous studies (Fortescue 285 
et al. 2007; Kosowski et al. 2019; Mehta et al. 2012; Neilan et al. 2006), where cardiac troponin 286 
release was inversely associated with training experience and weekly training mileage. It could 287 
be that our sample was more homogeneous in relation to training status compared to previous 288 




































































identified between post-race hs-TNT and self-reported training history. On the other hand, the 290 
lack of any association between post-race hs-TNT and baseline CPET variables (i.e., VO2max, 291 
maximal speed and speed attained at VT2) concurs with previous studies (Kosowski et al. 2019; 292 
Richardson et al. 2018; Trivax et al. 2010). Similarly, our results also coincides with preceding 293 
investigations where no relationships were showed between echocardiographic measures and hs-294 




































































5. Conclusions 296 
 297 
Runners who performed the marathon at a relative higher mean HR sustained a greater post-race 298 
hs-TNT rise. Moreover, participants who still displayed values above the URL for this biomarker 299 
24 h post-race, ran the marathon at a higher speed relative to their second ventilatory threshold 300 
and the peak speed reached at the CPET. Conversely, neither training history nor cardiopulmonary 301 
fitness were related to hs-TNT rise and normalization. These data lead us to suggest that running 302 
a marathon closer to each one individual’s limits, independently of training background and 303 
absolute cardiopulmonary fitness, provokes greater cardiac stress. 304 
 305 
Practical implications 306 
 307 
- Running a marathon induces significant cardiac stress. The magnitude of post-race 308 
troponin release is correlated with exercise relative intensity. 309 
- A longer post-race recovery time is recommended for those participants who run the 310 
marathon at a harder intensity, relative to their cardiopulmonary fitness.  311 
- Performing a CPET before the race and wearing a HR monitor during the marathon, 312 
especially in those participants with any cardiovascular risk factor, is strongly advocated 313 
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Figure legend 408 
Figure 1. Evolution of hs-TNT 409 
* Significantly different from baseline condition (p<0.05); # Significantly different from the 410 
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